Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6197 | 1.00 | NR1H2 (0.49) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL346504 | 1.00 | NR1H2 (0.49) | NR1H2HPGDKDM4EPKMMEN1 | |
| Hydrochloric Acid SCHEMBL28558235 | 0.98 | NR1H2 (0.48) | NR1H2HPGDKDM4EPKMMEN1 | |
| Hydrochloric Acid SCHEMBL1290905 | 0.98 | NR1H2 (0.48) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL28110777 | 0.92 | HPGD (0.51) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL640559 | 0.91 | MEN1 (0.54) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL1192567 | 0.91 | MEN1 (0.54) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL481736 | 0.91 | MEN1 (0.54) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL103083 | 0.90 | HPGD (0.54) | NR1H2HPGDKDM4EPKMMAPT | |
| Hydrochloric Acid SCHEMBL31587983 | 0.89 | MEN1 (0.53) | NR1H2HPGDMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113912594-B | Nitrothiophene methylamine optical isomer and medical application thereof | 中国人民解放军军事科学院军事医学研究院 | 2023-08-04 | — | — | CN | claimed |
| CN-113912594-A | Nitrothiophene methylamine optical isomer and medical application thereof | 中国人民解放军军事科学院军事医学研究院 | 2022-01-11 | — | — | CN | claimed |
| CN-108975292-A | A kind of preparation method of double fluorine sulfonyl imide compounds | 九江天赐高新材料有限公司 | 2018-12-11 | — | — | CN | claimed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-3912979-B1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4688743-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | University of Virginia Patent Foundation (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-12521399-B2 | Compound as voltage-gated sodium channel inhibitor | GUANGZHOU FERMION TECHNOLOGY CO., LTD. (CN) | 2026-01-13 | — | — | US | disclosed |
| EP-4463452-B1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250206745-A1 | PYRROLOPYRIDAZINE DERIVATIVES AND RELATED USES | NODTHERA LTD (GB) | 2025-06-26 | — | — | US | disclosed |
| WO-2005118531-A1 | AMINOMETHYL-AZACYCLE DERIVATIVES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050176738-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005047293-A1 | MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AND COMPOSITIONS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
| EP-1448566-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045942-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-5977097-A | 1-methylcarbapenem derivatives | SANKYO COMPANY LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| EP-0900797-A1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO COMPANY LIMITED (JP) | 1999-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | NR1H2 4598/4885HPGD 1092/4885KDM4E 1041/4885 |
| US-20250206745-A1 | PYRROLOPYRIDAZINE DERIVATIVES AND RELATED USES | IL1B, NLRP3, NLRP1 | NR1H2 3428/4885HPGD 115/4885KDM4E 3847/4885 |
| US-20050176738-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | MCHR1, MCHR2, MC1R | NR1H2 297/4885HPGD 1258/4885KDM4E 1117/4885 |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | ACKR3, CXCR2, CCL11 | NR1H2 119/4885HPGD 308/4885KDM4E 4881/4885 |
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | MYC, MYCBP, MYCBP2 | NR1H2 4408/4885HPGD 4555/4885KDM4E 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.